Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.
Shuo WangLi WangJianda HuWenbin QianXi ZhangYu HuQi ZhuBobin ChenDepei WuChung-Chou H ChangPengpeng XuXiaoyun ZhengJuying WeiYao LiuGuohui CuiYong TangYan MaHaiwen HuangHongmei YiWei Li ZhaoPublished in: Cancer communications (London, England) (2021)
This is the first large-scale Asian cohort study focusing on outcomes of refractory DLBCL. The definition of the SCHOLAR-1 study identifies patients with homogenously inferior survival, thus is appropriate to select refractory DLBCL. Due to poor clinical outcomes in the rituximab era, patients with refractory DLBCL may be potential candidates for novel treatment modalities.